Valuation: MORC HOLD

Market Cap 2.86B 2.5B 2.31B 2.12B 4.02B 276B 4.09B 27.59B 10.84B 135B 10.75B 10.51B 465B P/E 2022
-17.3x
P/E 2023 -8.04x
Enterprise Value 2.86B 2.5B 2.31B 2.12B 4.02B 276B 4.09B 27.59B 10.84B 135B 10.75B 10.51B 465B EV / Sales 2022
14,564,450x
EV / Sales 2023 2,757,343,865x
Free-Float
-
Yield 2022 *
-
Yield 2023 -
3 years 19.34
Extreme 19.345
62.08
5 years 19.23
Extreme 19.23
68.75
10 years 9.9
Extreme 9.9
93
Manager TitleAgeSince
President - -
Director of Finance/CFO 50 2020-04-05
Chief Tech/Sci/R&D Officer 57 2024-03-18
Director TitleAgeSince
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
8/16/24 Issuer sale

Chief Technology Officer

191,000 0.3803%
8/16/24 Tender

Chief Executive Officer

2,332,585 4.6443%
8/16/24 Issuer sale

General Counsel

561,952 1.1189%

Financials

2022 2023
Net sales 70.81M 61.89M 57.24M 52.52M 99.41M 6.82B 101M 683M 268M 3.33B 266M 260M 11.5B 521K 455K 421K 386K 731K 50.2M 744K 5.02M 1.97M 24.52M 1.96M 1.91M 84.64M
Net income -59.04M -51.61M -47.73M -43.8M -82.89M -5.69B -84.33M -569M -224M -2.78B -222M -217M -9.59B -152M -133M -123M -113M -214M -14.66B -217M -1.47B -576M -7.16B -571M -559M -24.71B
Net Debt -348.25 -304.4 -281.51 -258.32 -488.91 -33.56K -497.4 -3.36K -1.32K -16.39K -1.31K -1.28K -56.57K -704.35 -615.67 -569.37 -522.47 -988.84 -67.87K -1.01K -6.79K -2.67K -33.14K -2.65K -2.59K -114K
Logo MORC HOLD
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Employees
128
Sector
-
  1. Stock Market
  2. Stocks
  3. MORF Stock